Skip to Content
Discovering the causes of cancer and the means of prevention

TO BE DELETED Glioma Genome-Wide Association Study (GWAS)

Investigators from 16 prospective epidemiologic cohorts, part of the NCI Cohort Consortium, and a select number of case control studies established a cohort-based genome-wide association study (GWAS) of glioma ("GliomaScan"). GliomaScan is funded by the National Cancer Institute (NCI), and involves a genome-wide scan of common genetic variants to identify markers of susceptibility to glioma. Genotyping was conducted by the NCI Cancer Genomics Research (CGR) Laboratory.

DCEG investigators conducted a new, independent GWAS of glioma using 1,856 cases and 4,955 controls from 14 studies belonging to the NCI Cohort Consortium, three case-control studies, and one population-based case-only study. Cases were newly diagnosed glioma [ICDO-3 codes 9380-9480 or equivalent], and controls were cancer-free. Newly genotyped controls (n=2,429) were selected in a 2:1 ratio, frequency matched on age, sex and race/ethnicity. GWAS data were already available on 2,591 controls and 12 cases from cohorts that had participated in the PANSCAN, CGEMS, and the NCI lung cancer GWAS.


Obtain additional information or apply for data access to the Glioma Genome-Wide Association Study on the dbGaP website.